Increasing evidence has shown that mutations in SWI/SNF complex subunits confer resistance to several antineoplastic agents routinely used for the treatment of hematological malignancies, including ibrutinib, venetoclax, doxorubicin, paclitaxel or vinblastine. The gene discussed is SMARCA1; the disease is hematologic disorder.